- CA$1.20bn
- CA$1.89bn
- $770.89m
- 66
- 38
- 96
- 74
Annual income statement for Cresco Labs, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 129 | 476 | 822 | 843 | 771 |
| Cost of Revenue | |||||
| Gross Profit | 45.6 | 207 | 406 | 407 | 362 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 166 | 501 | 1,057 | 922 | 857 |
| Operating Profit | -38 | -24.4 | -235 | -79.4 | -86.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -50.8 | -64.2 | -257 | -127 | -147 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -65.3 | -92.8 | -297 | -216 | -180 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -43.2 | -102 | -320 | -212 | -176 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -43.2 | -102 | -320 | -212 | -176 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.446 | -0.478 | -0.414 | -0.447 | -0.243 |